JPRN-UMIN000035193已完成未知
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog. - Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with aphakic eye or implanted IOL in the eye (history of cataract surgery), Patients with cataract surgery scheduled (within the last 6 months) Patients with some corneal abnormality or other diseases which may interfere with accurate IOP measurement using Goldmann applanation tonometer Patients with a history of corneal refractive surgery Patients with active extraocular disease, inflammation or infection in the eye(s) or eyelid(s) Patients with allergy to the ingredients used in the present study Pregnant, lactating women or women who may be pregnant, and women who wish to be pregnant or can not conduct appropriate contraception during the study period
研究者
相似试验
招募中
不适用
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002%glaucoma or ocular hypertensionJPRN-UMIN000035240Inouye Eye Hospital100
招募中
不适用
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution.JPRN-UMIN000026231Inouye Eye Hospital100
已完成
不适用
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution.glaucoma or ocular hypertensionJPRN-UMIN000026224Inouye Eye Hospital100
已完成
不适用
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% ophthalmic solution.JPRN-UMIN000026230Inouye Eye Hospital100
暂停
3 期
EPOCIM in benign prostatic hyperplasia.Benign prostatic hyperplasiaRPCEC00000092Center of Molecular Immunology(CIM)306